EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade

Shaoyong Peng, Minshan Wu, Qian Yan, Gaopo Xu, Yumo Xie, Guannan Tang, Jinxin Lin, Zixu Yuan, Xiaoxia Liang, Ze Yuan, Jingrong Weng, Liangliang Bai und 5 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Shaoyong Peng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Glucose. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Project 5010 of Clinical Medical Research of Sun Yat-sen University-5010 Cultivation Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy is beneficial for some colorectal cancer (CRC) patients, but immunosuppressive networks limit its effectiveness. Cancer‐associatedfibroblasts (CAFs) are significant in immune escape and resistance toimmunotherapy, emphasizing the urgent need for new treatment strategies.

Methods

Flow cytometric, Western blotting, proteomics analysis, analysis of public database data, genetically modified cell line models, T cell coculture, crystal violetstaining, ELISA, metabonomic and clinical tumour samples were conducted to assess the role of EDEM3 in immune escape and itsmolecular mechanisms. We evaluated theeffects of FMD plus 2‐DG on antitumour immunity using multipleximmunofluorescence, flow cytometry, cytokine profiling, TUNEL assays, xenografttumours, and in vivo studies.

Results

We show thatCAFs upregulate PD‐L1 glycosylation and contribute to immune evasion byglycosyltransferase EDEM3. Additionally, EDEM3 plays a role in tumour immunityduring tumour progression. However, the EDEM3‐mediated upregulation of PD‐L1 expression underpins PD‐1/PD‐L1 blockade resistance in vivo. This finding contradictsthe previous trend that positive PD‐L1 expression indicates a strong responseto PD‐1/PD‐L1 blockade. Mechanistically, high‐EDEM3 expression facilitates M2‐like This finding contradictsthe previous trend that positive PD‐L1 expression indicates a strong responseto PD‐1/PD‐L1 blockade.Mechanistically, polarizationand chemotactic migration of macrophages, which are enriched in theperipheral region of tumours compared to thecore region, precluding access of CD8+ T cells to tumourfoci. Furthermore, we EDEM3 predominantly activates the recruited M2‐like macrophagesvia a glucose metabolism‐dependent mechanism. Manipulationof glucose utilization by a fasting‐mimicking diet(FMD) plus 2‐DG treatmentsynergistically with PD‐1 antibody elicits potent antitumour activity byeffectively decreasing tumour glycosylated PD‐L1 expression, augmenting the CD8+effector T cell infiltration and activation while concurrently reducing the infiltration.TheCAFs‐EDEM3‐M2‐like macrophage axis plays a critical role in promotingimmunotherapy resistance. infiltration.TheCAFs‐EDEM3‐M2‐like macrophage axis plays a critical role in promotingimmunotherapy resistance.

Conclusions

Our study suggests that blocking EDEM3‐induced M2‐like macro phage trafficking by FMD plus 2‐DG is a promising and effective strategy to overcomeresistance to checkpoint blockade therapy offeringhope for improved treatment outcomes. Key points Cancer‐associated fibroblasts (CAFs) can enhance PD‐L1 glycosylation through the glycosyltransferase EDEM3, contributing to immune evasion during tumour progression. EDEM3 predominantly activates the recruit M2‐like macrophages via a glucose metabolism‐dependent mechanism. Blocking glucose utilization antagonizes recruiting and polarizing M2‐like macrophages synergistically with PD‐1 antibody to improve anticancer immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucoseHumansMiceAnimalsMacrophagesB7-H1 AntigenImmune Checkpoint InhibitorsColorectal NeoplasmsDrug Resistance, NeoplasmMembrane ProteinsProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

2‐DGM2‐like macrophagePD‐L1 glycosylationantitumour immunitycancer‐associated fibroblastsfasting‐mimicking dietglycosyltransferase EDEM3

Substanzen

GlucoseB7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanMembrane ProteinsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, Guangzhou, China.
  • School of Life Sciences, Innovation Center of the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Huichuan Yu, Xiaoxia Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Project 5010 of Clinical Medical Research of Sun Yat-sen University-5010 Cultivation Foundation
  • Science and Technology Program of Guangzhou
  • Scientific Research Project of the Sixth Affiliated Hospital of Sun Yat-Sen University
  • Talent Project of the Sixth Affiliated Hospital of Sun Yat-sen University
  • Excellent Talent Training Project of the Sixth Affiliated Hospital of Sun Yat-sen University
  • Sixth Affiliated Hospital of Sun Yat-sen University Clinical Research-'1010' Program

Zitieren

APA

Peng, S., Wu, M., Yan, Q., Xu, G., Xie, Y., Tang, G., Lin, J., Yuan, Z., Liang, X., Yuan, Z., Weng, J., Bai, L., Wang, X., Yu, H., Huang, M., Luo, Y., & Liu, X. (2025). Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70161

Vancouver

Peng S, Wu M, Yan Q, Xu G, Xie Y, Tang G, et al. Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70161

BibTeX
@article{Peng2025,
  author = {Peng, Shaoyong and Wu, Minshan and Yan, Qian and Xu, Gaopo and Xie, Yumo and Tang, Guannan and Lin, Jinxin and Yuan, Zixu and Liang, Xiaoxia and Yuan, Ze and Weng, Jingrong and Bai, Liangliang and Wang, Xiaolin and Yu, Huichuan and Huang, Meijin and Luo, Yanxin and Liu, Xiaoxia},
  title = {Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70161}
}
Kostenlos starten →